Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

1.

Intravenous zoledronic acid in postmenopausal women with low bone mineral density.

Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.

N Engl J Med. 2002 Feb 28;346(9):653-61.

3.

Once-yearly zoledronic acid in the prevention of osteoporotic bone fractures in postmenopausal women.

Lambrinoudaki I, Vlachou S, Galapi F, Papadimitriou D, Papadias K.

Clin Interv Aging. 2008;3(3):445-51. Review.

4.

Annual zoledronic acid for osteoporosis.

BMJ Group.

Drug Ther Bull. 2008 Dec;46(12):93-6. Review.

PMID:
19056701
5.

Use of bisphosphonates in the management of postmenopausal osteoporosis.

Papapoulos SE.

Ann N Y Acad Sci. 2011 Feb;1218:15-32. doi: 10.1111/j.1749-6632.2010.05767.x. Epub 2010 Sep 29. Review.

PMID:
20946579
6.

Role of zoledronic acid in the prevention and treatment of osteoporosis.

Räkel A, Boucher A, Ste-Marie LG.

Clin Interv Aging. 2011;6:89-99. doi: 10.2147/CIA.S7282. Epub 2011 Mar 28. Review.

7.

Management of osteoporosis in the aging male: focus on zoledronic acid.

Piper PK Jr, Gruntmanis U.

Clin Interv Aging. 2009;4:289-303. Epub 2009 Jun 29. Review.

8.

A review of minodronic acid hydrate for the treatment of osteoporosis.

Tanishima S, Morio Y.

Clin Interv Aging. 2013;8:185-9. doi: 10.2147/CIA.S23927. Epub 2013 Feb 15. Review.

9.

Zoledronic acid: a review of its use in the treatment of osteoporosis.

Deeks ED, Perry CM.

Drugs Aging. 2008;25(11):963-86. doi: 10.2165/0002512-200825110-00007. Review.

PMID:
18947264
11.

A clinician's perspective on the use of zoledronic acid in the treatment of postmenopausal osteoporosis.

Lewiecki EM.

J Clin Densitom. 2008 Oct-Dec;11(4):478-84. doi: 10.1016/j.jocd.2008.07.003. Epub 2008 Aug 30. Review.

PMID:
18757222
12.
13.

[Zoledronic acid reduces risk of any new clinical fracture and risk of death after surgical repair of a low-trauma hip fracture].

Leszczyński P.

Chir Narzadow Ruchu Ortop Pol. 2010 May-Jun;75(3):168-71. Review. Polish.

PMID:
21038635
14.

Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review.

Eriksen EF, Díez-Pérez A, Boonen S.

Bone. 2014 Jan;58:126-35. doi: 10.1016/j.bone.2013.09.023. Epub 2013 Oct 9. Review.

PMID:
24120384
16.

The role of zoledronic acid in the management of osteoporosis.

Maricic M.

Clin Rheumatol. 2010 Oct;29(10):1079-84. doi: 10.1007/s10067-010-1486-3. Epub 2010 Jun 11. Review.

PMID:
20544246
17.

Intravenous zoledronic acid for the treatment of osteoporosis.

Lewiecki EM.

Curr Osteoporos Rep. 2008 Mar;6(1):17-23. Review.

PMID:
18430396
18.

Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.

Reginster JY, Malaise O, Neuprez A, Jouret VE, Close P.

Drugs Aging. 2007;24(5):351-9. Review.

19.

Efficacy of intravenous zoledronic acid in the prevention and treatment of osteoporosis: a meta-analysis.

Zhang J, Wang R, Zhao YL, Sun XH, Zhao HX, Tan L, Chen DC, Hai-Bin X.

Asian Pac J Trop Med. 2012 Sep;5(9):743-8. doi: 10.1016/S1995-7645(12)60118-7. Review.

20.

Managing bone health with zoledronic acid: a review of randomized clinical study results.

Hadji P.

Climacteric. 2011 Jun;14(3):321-32. doi: 10.3109/13697137.2010.529966. Epub 2010 Dec 23. Review.

PMID:
21182431

Supplemental Content

Support Center